We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.79%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$119M
Cap. Flow
+$19.1M
Cap. Flow %
1.01%
Top 10 Hldgs %
50.01%
Holding
78
New
5
Increased
8
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$23.9M
2
GERN icon
Geron
GERN
+$18.1M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
FATE icon
Fate Therapeutics
FATE
+$16.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$14.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$22.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.7M
3
BPMC
Blueprint Medicines
BPMC
+$18.1M
4
VERU icon
Veru
VERU
+$17.7M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
26
PMV Pharmaceuticals
PMVP
$59.2M
$27.5M 1.45%
3,163,795
– –
BLU
27
DELISTED
BELLUS Health Inc.
BLU
$26.3M 1.39%
3,200,000
– –
DAWN
28
DELISTED
Day One Biopharmaceuticals
DAWN
$25.6M 1.35%
1,189,943
– –
RNAM
29
DELISTED
Avidity Biosciences
RNAM
$24.9M 1.31%
1,121,327
– –
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$23.7M 1.25%
600,000
– –
GERN icon
31
Geron
GERN
$828M
$19.6M 1.03%
+8,100,000
New +$18.1M
EXEL icon
32
Exelixis
EXEL
$13.3B
$18.4M 0.97%
1,150,000
-100,000
-8% -$1.63M
PNT
33
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$18.2M 0.96%
2,500,000
– –
PRTA icon
34
Prothena Corp
PRTA
$425M
$18.1M 0.95%
300,000
– –
ETNB
35
DELISTED
89bio
ETNB
$17.8M 0.94%
1,400,000
– –
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.7M 0.93%
+825,000
New +$17.6M
RAIN
37
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$17.2M 0.91%
2,147,212
+972,212
+83% +$6.1M
VKTX icon
38
Viking Therapeutics
VKTX
$3.7B
$14.1M 0.74%
+1,500,000
New +$6.7M
NRIX icon
39
Nurix Therapeutics
NRIX
$2.41B
$13.4M 0.71%
1,224,892
– –
FATE icon
40
Fate Therapeutics
FATE
$286M
$12.6M 0.66%
1,250,000
+900,000
+257% +$16.9M
ASND icon
41
Ascendis Pharma A/S
ASND
$16B
$11.6M 0.61%
95,000
+25,000
+36% +$2.9M
CGEM icon
42
Cullinan Oncology
CGEM
$1.01B
$11.3M 0.6%
1,074,082
– –
IOVA icon
43
Iovance Biotherapeutics
IOVA
$1.82B
$9.62M 0.51%
1,505,133
-430,000
-22% -$3.36M
ORIC icon
44
Oric Pharmaceuticals
ORIC
$1.15B
$7.36M 0.39%
1,054,000
– –
GOSS icon
45
Gossamer Bio
GOSS
$82.9M
$7.24M 0.38%
3,336,928
-235,000
-7% -$1.93M
PANA
46
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$6.21M 0.33%
500,000
– –
COGT icon
47
Cogent Biosciences
COGT
$6.65B
$6.07M 0.32%
525,000
+100,000
+24% +$1.24M
BCAB icon
48
BioAtla
BCAB
$5.46M
$5.66M 0.3%
13,727
– –
ARVN icon
49
Arvinas
ARVN
$518M
$5.13M 0.27%
+150,000
New +$6.31M
CABA icon
50
Cabaletta Bio
CABA
$437M
$5M 0.26%
540,000
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Boxer Capital held 78 positions worth $1.9B, up 6.7% from $1.78B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Boxer Capital's Q4 2022 filing shows 5 new, 8 increased, 9 reduced and 7 closed positions. Its largest new stake was Axsome Therapeutics: 400,000 shares worth $30.9M. The largest sale was Sarepta Therapeutics, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2022 buy was Axsome Therapeutics: 400,000 shares worth $30.9M.
  • Boxer Capital added most to Fate Therapeutics in Q4 2022, an estimated $16.9M increase.
  • Boxer Capital's biggest Q4 2022 reduction was Veru, cutting an estimated $17.7M.
  • Boxer Capital fully exited Sarepta Therapeutics in Q4 2022, selling an estimated $22.1M.
  • Boxer Capital's ten largest holdings make up 50% of its $1.9B portfolio in Q4 2022.
  • Boxer Capital opened 5 new positions and closed 7 in Q4 2022.
  • Boxer Capital's portfolio value rose 6.7% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.